Coiteux, Valérie

Evaluation of residual disease and TKI duration are critical predictive factors for molecular recurrence after stopping imatinib first-line in chronic phase CML patients

Nicolini, F. E., Dulucq, S., Boureau, L., Cony-Makhoul, P., Charbonnier, A., Escoffre-Barbe, M., Rigal-Huguet, F., Coiteux, V., Varet, B., Dubruille, V., et al. (2019) · Clinical Cancer Research

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 111

Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients

Rousselot, P., Mollica, L., Guilhot, J., Guerci, A., Nicolini, F. E., Etienne, G., Legros, L., Charbonnier, A., Coiteux, V., Dartigeas, C., et al. (2021) · British Journal of Haematology

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 46